TNXP Tonix Pharmaceuticals Holding Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: TNXP

Price (delayed)

$11.93

Market cap

$190.17M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$14.53

Enterprise value

$5.99M

?
Relative Growth: Rel. Growth: 63
Relative Strength: Rel. Strength: 6
Relative Valuation: Rel. Valuation: 9
Relative Profitability: Rel. Profitability: 16

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix's ...

Highlights
TNXP's EPS has soared by 99% YoY
TNXP's gross margin has soared by 97% YoY and by 19% from the previous quarter
The company's equity rose by 26% YoY but it fell by 7% QoQ
The debt has surged by 129% year-on-year
TNXP's quick ratio is down by 41% YoY and by 6% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.tonixpharma.com
Peers: SCYX ANIP UTHR

Key stats

What are the main financial stats of TNXP

TNXP stock price

How has the Tonix Pharmaceuticals Holding stock price performed over time
Intraday
4.65%
1 week
-5.62%
1 month
-8.44%
1 year
-69.37%
YTD
-23.62%
QTD
-13.24%

Financial performance

How have Tonix Pharmaceuticals Holding's revenue and profit performed over time
Revenue
$17.56M
Gross profit
$10.28M
Operating income
-$151.19M
Net income
-$147.39M
Gross margin
58.6%
Net margin
-839.5%
TNXP's gross margin has soared by 97% YoY and by 19% from the previous quarter
The company's revenue has surged by 75% YoY and by 34% QoQ
The gross profit has soared by 59% from the previous quarter
The net margin rose by 36% year-on-year and by 11% since the previous quarter

Price vs fundamentals

How does TNXP's price correlate with its fundamentals

Growth

What is Tonix Pharmaceuticals Holding's growth rate over time

Valuation

What is Tonix Pharmaceuticals Holding stock price valuation
P/E
N/A
P/B
0.7
P/S
9.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.34
TNXP's EPS has soared by 99% YoY
The P/B is 34% higher than the 5-year quarterly average of 0.5 but 33% lower than the last 4 quarters average of 1.0
The company's equity rose by 26% YoY but it fell by 7% QoQ
The company's revenue has surged by 75% YoY and by 34% QoQ
TNXP's P/S is 48% below its last 4 quarters average of 17.2

Efficiency

How efficient is Tonix Pharmaceuticals Holding business performance
The company's return on equity rose by 44% YoY but it fell by 12% QoQ
TNXP's return on invested capital is down by 44% year-on-year and by 23% since the previous quarter
TNXP's ROA is up by 40% YoY but it is down by 11% QoQ
TNXP's ROS is up by 36% YoY and by 11% from the previous quarter

Dividends

What is TNXP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TNXP.

Financial health

How did Tonix Pharmaceuticals Holding financials performed over time
Tonix Pharmaceuticals Holding's total liabilities has soared by 147% YoY but it has decreased by 3.9% from the previous quarter
The current ratio has declined by 43% year-on-year and by 6% since the previous quarter
The debt is 99% smaller than the equity
The debt has surged by 129% year-on-year
The company's equity rose by 26% YoY but it fell by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.